{"id":"W4392718644","doi":"10.1016/j.eururo.2024.01.007","title":"Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Astellas Pharma; Astellas Pharma US; Seagen; Pfizer","keywords":"Medicine; Discontinuation; Chemotherapy; Quality of life (healthcare); Internal medicine; Confidence interval; Chemotherapy regimen; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002185229,0.0005563908,0.001841157,0.0002042501,0.0003338697,0.0007191165,0.0004736349,0.000850789,0.002388732],"category_scores_gemma":[0.001044387,0.0002518986,0.001385624,0.0002862531,0.0006159951,0.0005635816,0.0004177006,0.002146105,0.0002875468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004955619,"about_ca_system_score_gemma":0.0008252269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003797848,"about_ca_topic_score_gemma":0.001054194,"domain_scores_codex":[0.9993286,0.0004361733,0.00003971219,0.00005222997,0.00005868264,0.00008455412],"domain_scores_gemma":[0.9992179,0.0002246902,0.0001826567,0.00006007345,0.00004432708,0.0002704199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8821315,0.03300167,0.009379128,0.0009468167,0.0009950825,0.0001457339,0.0001916782,0.001221184,0.009149645,0.0001360654,0.0009497273,0.06175179],"study_design_scores_gemma":[0.441118,0.5275928,0.0256987,0.0001038104,0.0005144584,0.0003122973,0.0001187532,0.001401915,0.001661029,0.0002036558,0.001246327,0.00002835204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975736,0.001315069,0.0000721762,0.0001390325,0.00003895998,0.0003365183,0.000143982,0.000007242693,0.0003733832],"genre_scores_gemma":[0.9969784,0.0007863645,0.0003601297,0.0003038283,0.00008541182,0.0006476127,0.0004340778,0.000004018465,0.0004001712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002388732,"threshold_uncertainty_score":0.01155674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02773329007438211,"score_gpt":0.3133052471279636,"score_spread":0.2855719570535815,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}